Marengo Therapeutics Unveils First Clinical Data for Invikafusp Alfa
Marengo Therapeutics, Inc., a pioneering biotechnology company focused on precision T cell activation, is set to present its first-in-human clinical data for Invikafusp alfa (STAR0602) during a late-breaking oral presentation at the Society for Immunotherapy of Cancer's annual meeting. This event, scheduled to unfold in the near future, promises to showcase transformative developments in the fight against cancer.
Highlighting Groundbreaking T Cell Technology
At the core of Marengo's innovative approach is its unique T cell activator technology, which focuses on V? chain targeting. This technique is fundamental in rejuvenating immune responses against tumors that have proved resistant to conventional therapies. The company is conducting an ongoing Phase 1/2 clinical trial, named STARt-001, which is evaluating Invikafusp alfa as a single-agent treatment for those wickedly challenging PD(L)1 resistant cancers.
Details of the Upcoming Presentation
The details surrounding Marengo's presentation are highly anticipated:
- Title: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR ? chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1.
- Conference: 39th SITC Annual Meeting.
- Abstract Number: LBA-1470.
- Session Title: Late-Breaking Abstract Session 2.
- Session Date and Time: Set for a Saturday afternoon slot.
- Presenter: Dr. James L. Gulley from the National Cancer Institute.
This presentation marks the first disclosure of preliminary clinical results from the STARt-001 study, which is particularly exciting for the medical community and investors alike.
About Marengo Therapeutics
Founded on a vision to transform cancer treatment, Marengo Therapeutics is a clinical-stage biotechnology company committed to developing innovative therapies that activate T cells selectively. The company utilizes its proprietary Selective T Cell Activation Repertoire (STAR™) platform, which strategically engages distinct T cell subsets by focusing on the V? chain of the T cell receptor (TCR). This engagement enhances the immune system's capability to combat cancer effectively.
Innovation Through the STAR™ Platform
The STAR™ platform embodies Marengo's cutting-edge approach, employing a multi-specific antibody-fusion technology that derives from a unique library targeting germline-encoded variable V? regions of the TCR. By fusing these antibodies with T cell co-stimulatory elements, Marengo aims to establish prolonged anti-tumor immune responses.
Examining Invikafusp Alfa (STAR0602)
Invikafusp alfa stands out as Marengo's flagship candidate from the STAR™ platform. Designed to activate a common V? T cell subset that is present across many cancers, Invikafusp alfa combines a non-clonal mode of TCR activation with co-stimulatory signals, offering a fresh approach to enhance anti-tumor immunity.
STARt-001 Clinical Trial Insights
The STARt-001 clinical trial is pivotal in assessing the safety, tolerability, and preliminary effectiveness of Invikafusp alfa as a monotherapy for advanced antigen-rich solid tumors. This includes rarer tumor types and those resistant to PD-1 inhibition. The trial comprises two phases: an initial Phase 1 dose escalation followed by a Phase 2 dose expansion.
For those interested in clinical trial participation, Marengo has provided contact details for potential candidates wishing to join this significant study.
Frequently Asked Questions
What is Invikafusp alfa?
Invikafusp alfa (STAR0602) is Marengo's leading T cell activator designed to enhance anti-tumor immune responses in patients with challenging cancers.
Where will the presentation take place?
The presentation will be held at the Society for Immunotherapy of Cancer's annual meeting.
What distinguishes Marengo's STAR platform?
The STAR platform offers multi-specific antibody-fusion technology targeting unique T cell receptor regions to promote robust immune responses.
What can attendees expect from the presentation?
Attendees will gain early insights from the pivotal STARt-001 study concerning the efficacy and safety of Invikafusp alfa.
How is Invikafusp alfa administered in the trial?
As a monotherapy, Invikafusp alfa is administered to biomarker-selected patients with a focus on advanced antigen-rich solid tumors.
